Skip to main content
OpenTrials
Completed

NCT Number: NCT06428890

Effect of 7 Days of Grape Seed Extract Supplementation on Cold Pressor Test and Muscle Metaboreflex in Individuals With Elevated and Stage 1 Hypertension

This study aimed to assess the effect of the supplementation with grape seed extract (GSE) on blood pressure during static handgrip exercise and muscle metaboreflex in individuals with elevated and state 1 hypertension.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prehypertension Cardiovascular Diseases Vascular Diseases

Age range

18 year–30 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

California Baptist University

Riverside, California, 92504, United States

About this study

Muscle metatoreflex (MMR) has been known to play an important role in adjusting hemodynamic responses during exercise. The reflex increases sympathetic activity to heart and blood vessels to increase blood supply to contracting skeletal muscles. On the other hand, studies demonstrated that abnormal cardiovascular responses occurred by the overactive MMR in pathological conditions such as hypertension, diabetes, and congestive heart failure. Excessive blood pressure (BP) responses to exercise induce cardiovascular events such as stroke, heart attack, and coronary artery disease. Previously, a study found that dietary supplementation with grape seed extract (GSE) reduced BP response to dynamic exercise in individuals with elevated and stage 1 hypertension (ES1H) and associated with peripheral vasodilation. However, mechanisms underlying this phenomenon are not clear. Purpose: therefore, the purpose of this study is to investigate whether chronic dietary supplementation with GSE can decrease BP responses to exercise and this observation is associated with reduced MMR. Methods: 12 ES1H males were studied. Changes in cardiac output (Q), mean arterial pressure (MAP) and total peripheral resistance (TPR) were compared between the GSE and placebo supplementations during static handgrip exercise (SHE) and post exercise muscular ischemia (PEMI). Participants completed 3 min of SHE at 40% of MVC followed by 2 min of PEMI.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • systolic blood pressure: 120-139 mmHg and/or a diastolic blood pressure: 80-89 mmHg

Exclusion criteria

  • taking medications that could affect cardiovascular function or BP

Treatment and study plan

Grape seed extract

Dietary Supplement

dietary supplements that rich in polyphenolic compounds

Placebo

Dietary Supplement

Starch

Primary outcomes

  1. heart rate (bpm)

    Time frame: 5 minutes, 3 minutes, and 2 minutes, respectively.

    measured these variables at rest and during static handgrip exercise and muscle metaboreflex

  2. stroke volume (ml)

    Time frame: 5 minutes, 3 minutes, and 2 minutes, respectively.

    measured these variables at rest and during static handgrip exercise and muscle metaboreflex

  3. cardiac output (l/min)

    Time frame: 5 minutes, 3 minutes, and 2 minutes, respectively.

    measured these variables at rest and during static handgrip exercise and muscle metaboreflex

  4. systolic blood pressure (mmHg)

    Time frame: 5 minutes, 3 minutes, and 2 minutes, respectively.

    measured these variables at rest and during static handgrip exercise and muscle metaboreflex

  5. diastolic blood pressure (mmHg)

    Time frame: 5 minutes, 3 minutes, and 2 minutes, respectively.

    measured these variables at rest and during static handgrip exercise and muscle metaboreflex

  6. total peripheral resistance (mmHg/l/min)

    Time frame: 5 minutes, 3 minutes, and 2 minutes, respectively.

    measured these variables at rest and during static handgrip exercise and muscle metaboreflex

Sponsors and collaborators

Lead sponsor

California Baptist University

Other

Registry information

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
May 24, 2024
Registry last updated
May 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.